Frequently Asked Questions
The market is segmented based on , By Type (Myocardial muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia Modified Albumin (IMA)), Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis), Location of Testing (Point of Care, Laboratory) – Industry Trends and Forecast to 2030.
.
The Global Cardiac Biomarkers Testing Market size was valued at USD 12098.97 USD Billion in 2022.
The Global Cardiac Biomarkers Testing Market is projected to grow at a CAGR of 11.3% during the forecast period of 2023 to 2030.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
